Grateful Hippie Handmade Crafts Blog

UK pharmaceutical company GW Pharma is seeking FDA approval of their Sativex medication in the U.S. by the end of 2013. Sativex, the brand name for Nabiximols, is a cannabinoid-based mouth spray that orally delivers a fixed dose of 2.7 mg of delta 9-THC and 2.5 mg of cannabidiol, the latter being the cannabis chemical compound activating cannabinoid receptors in the human body that aid in pain management.
 
Sativex is presently in Phase III (advanced) FDA clinical trials for the …More
HIGHTIMES.COM – news

This entry was posted on Thursday, January 26th, 2012 at 12:00 am and is filed under 420 and with tags: Advanced, Sativex, Trials . You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.